Autolus Therapeutics plc (AUTL)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD

2.9400

+0.1000

(+3.52%)

At close: 04:00PM EST

2.9100

-0.03

(-1.02%)

After hours:

06:28PM EST

Trade prices are not sourced from all markets

All

TipRanks
Autolus Therapeutics upgraded to Buy from Neutral at Goldman Sachs
Goldman Sachs upgraded Autolus Therapeutics (AUTL) to Buy from Neutral with a price target of $7.60, up from $7. The recent approval of lead asset Aucatzyl represents a de-risking event for the company’s technology platform and manufacturing facilities and the label granted by the FDA supports Aucatzyl’s differentiated safety profile, contends the firm, which sees “a significant dislocation between the company’s fundamental valuation and current market value.” Published first on TheFly – the ult
Simply Wall St.
Autolus Therapeutics Third Quarter 2024 Earnings: US$0.31 loss per share (vs US$0.26 loss in 3Q 2023)
Autolus Therapeutics ( NASDAQ:AUTL ) Third Quarter 2024 Results Key Financial Results Net loss: US$82.1m (loss widened...